// App-Quantinova.ai

OP0313 : THERAPEUTIC APPROACHES TO OSTEOSARCOPENIA: DENOSUMAB EFFECT ON FALLS RISK, PHYSICAL PERFORMANCE AND WALKING SPEED

Researchers

Presenter

  • Y. El Miedany

Principal Investigators

  • M. El Gaafary

  • M. Toth

  • M. O. Hegazi

  • N. El Aroussy

  • W. Hassan

  • S. Almedany

  • A. Nasr

  • S. Bahlas

Medical Centers

  • Medway Hospital, Rheumatology, Gravesend, United Kingdom

  • Ain Shams University, Community and Public Health, Cairo, Egypt

  • Darenth Valley Hospital, Medicine, Dartford, United Kingdom

  • Adan Hosp, Kuwait, Kuwait

  • Ain Shams University Faculty of Medicine, Rheumatology and Rehabilitation, Cairo, Egypt

  • Ain Shams University Faculty of Medicine, Rheumatology and Rehabilitation, Cairo, Egypt

  • Tanta University, Rheumatology and Rehabilitation, Tanta, Egypt

  • Ain Shams University Cairo Egypt, Cairo, Egypt

  • King Abdulaziz University, Jeddah, Saudi Arabia

Locations

  • United Kingdom

  • Egypt

  • Kuwait

  • Saudi Arabia

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Osteoporosis

Biomarkers

  • Alveolar Soft Part Sarcoma Chromosome Region, Candidate 1

  • Bone Mineral Density

Drug/Treatment

  • Alendronate sodium

  • Zolendronic acid

  • Denosumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved